Your browser doesn't support javascript.
loading
Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon.
Fokam, Joseph; Essomba, Rene Ghislain; Njouom, Richard; Okomo, Marie-Claire A; Eyangoh, Sara; Godwe, Celestin; Tegomoh, Bryan; Otshudiema, John O; Nwobegahay, Julius; Ndip, Lucy; Akenji, Blaise; Takou, Desire; Moctar, Mohamed M M; Mbah, Cleophas Kahtita; Ndze, Valantine Ngum; Maidadi-Foudi, Martin; Kouanfack, Charles; Tonmeu, Sandrine; Ngono, Dorine; Nkengasong, John; Ndembi, Nicaise; Bissek, Anne-Cecile Z K; Mouangue, Christian; Ndongo, Chanceline B; Epée, Emilienne; Mandeng, Nadia; Kamso Belinga, Sandrine; Ayouba, Ahidjo; Fernandez, Nicolas; Tongo, Marcel; Colizzi, Vittorio; Halle-Ekane, Gregory-Edie; Perno, Carlo-Federico; Ndjolo, Alexis; Ndongmo, Clement B; Shang, Judith; Esso, Linda; de-Tulio, Oliviera; Diagne, Moussa Moise; Boum, Yap; Mballa, Georges A E; Njock, Louis R.
Afiliação
  • Fokam J; National Public Health Emergencies Operations Coordination Centre (NPHEOCC), Ministry of Public Health, Yaoundé, Cameroon. josephfokam@gmail.com.
  • Essomba RG; COVID-19 Genomic Surveillance Platform (PSG), Ministry of Public Health, Yaoundé, Cameroon. josephfokam@gmail.com.
  • Njouom R; Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon. josephfokam@gmail.com.
  • Okomo MA; Faculty of Health Sciences (FHS), University of Buea, Buea, Cameroon. josephfokam@gmail.com.
  • Eyangoh S; COVID-19 Genomic Surveillance Platform (PSG), Ministry of Public Health, Yaoundé, Cameroon.
  • Godwe C; National Public Health Laboratory (NPHL), Ministry of Public Health, Yaoundé, Cameroon.
  • Tegomoh B; Faculty of Medicine and Biomedical Sciences (FMBS), University of Yaounde I, Yaounde, Cameroon.
  • Otshudiema JO; COVID-19 Genomic Surveillance Platform (PSG), Ministry of Public Health, Yaoundé, Cameroon.
  • Nwobegahay J; Centre Pasteur du Cameroun (CPC), Yaoundé, Cameroon.
  • Ndip L; COVID-19 Genomic Surveillance Platform (PSG), Ministry of Public Health, Yaoundé, Cameroon.
  • Akenji B; National Public Health Laboratory (NPHL), Ministry of Public Health, Yaoundé, Cameroon.
  • Takou D; Faculty of Medicine and Biomedical Sciences (FMBS), University of Yaounde I, Yaounde, Cameroon.
  • Moctar MMM; COVID-19 Genomic Surveillance Platform (PSG), Ministry of Public Health, Yaoundé, Cameroon.
  • Mbah CK; Centre Pasteur du Cameroun (CPC), Yaoundé, Cameroon.
  • Ndze VN; Centre de Recherche en Maladies Emergentes et Re-emergentes (CREMER), Yaounde, Cameroon.
  • Maidadi-Foudi M; School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
  • Kouanfack C; World Health Organization (WHO), Cameroon Country Office, Yaounde, Cameroon.
  • Tonmeu S; COVID-19 Genomic Surveillance Platform (PSG), Ministry of Public Health, Yaoundé, Cameroon.
  • Ngono D; Centre de Recherche Pour la Santé des Armées (CRESAR), Ministry of Defence, Yaoundé, Cameroon.
  • Nkengasong J; Faculty of Health Sciences (FHS), University of Buea, Buea, Cameroon.
  • Ndembi N; National Public Health Laboratory (NPHL), Ministry of Public Health, Yaoundé, Cameroon.
  • Bissek AZK; Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
  • Mouangue C; USAID's Infectious Diseases Detection and Surveillance, Yaounde, Cameroon.
  • Ndongo CB; USAID's Infectious Diseases Detection and Surveillance, Yaounde, Cameroon.
  • Epée E; Faculty of Health Sciences (FHS), University of Buea, Buea, Cameroon.
  • Mandeng N; African Society for Laboratory Medicine (ASLM), Yaounde, Cameroon.
  • Kamso Belinga S; Centre de Recherche en Maladies Emergentes et Re-emergentes (CREMER), Yaounde, Cameroon.
  • Ayouba A; Centre de Recherche en Maladies Emergentes et Re-emergentes (CREMER), Yaounde, Cameroon.
  • Fernandez N; National Public Health Laboratory (NPHL), Ministry of Public Health, Yaoundé, Cameroon.
  • Tongo M; School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
  • Colizzi V; Africa Centres for Disease Control and Prevention (Africa CDC), Addis-Ababa, Ethiopia.
  • Halle-Ekane GE; Africa Centres for Disease Control and Prevention (Africa CDC), Addis-Ababa, Ethiopia.
  • Perno CF; Faculty of Health Sciences (FHS), University of Buea, Buea, Cameroon.
  • Ndjolo A; Division for Operational Health Research (DROS), Ministry of Public Health, Yaoundé, Cameroon.
  • Ndongmo CB; National Public Health Emergencies Operations Coordination Centre (NPHEOCC), Ministry of Public Health, Yaoundé, Cameroon.
  • Shang J; Department of Disease, Epidemic and Pandemic Control (DLMEP), Ministry of Public Health, Yaounde, Cameroon.
  • Esso L; National Public Health Emergencies Operations Coordination Centre (NPHEOCC), Ministry of Public Health, Yaoundé, Cameroon.
  • de-Tulio O; Department of Disease, Epidemic and Pandemic Control (DLMEP), Ministry of Public Health, Yaounde, Cameroon.
  • Diagne MM; Faculty of Medicine and Pharmaceutical Sciences (FMPS), University of Douala, Douala, Cameroon.
  • Boum Y; National Public Health Emergencies Operations Coordination Centre (NPHEOCC), Ministry of Public Health, Yaoundé, Cameroon.
  • Mballa GAE; Faculty of Medicine and Biomedical Sciences (FMBS), University of Yaounde I, Yaounde, Cameroon.
  • Njock LR; Department of Disease, Epidemic and Pandemic Control (DLMEP), Ministry of Public Health, Yaounde, Cameroon.
Sci Rep ; 13(1): 21654, 2023 12 08.
Article em En | MEDLINE | ID: mdl-38066020
ABSTRACT
While the SARS-CoV-2 dynamic has been described globally, there is a lack of data from Sub-Saharan Africa. We herein report the dynamics of SARS-CoV-2 lineages from March 2020 to March 2022 in Cameroon. Of the 760 whole-genome sequences successfully generated by the national genomic surveillance network, 74% were viral sub-lineages of origin and non-variants of concern, 15% Delta, 6% Omicron, 3% Alpha and 2% Beta variants. The pandemic was driven by SARS-CoV-2 lineages of origin in wave 1 (16 weeks, 2.3% CFR), the Alpha and Beta variants in wave 2 (21 weeks, 1.6% CFR), Delta variants in wave 3 (11 weeks, 2.0% CFR), and omicron variants in wave 4 (8 weeks, 0.73% CFR), with a declining trend over time (p = 0.01208). Even though SARS-CoV-2 heterogeneity did not seemingly contribute to the breadth of transmission, the viral lineages of origin and especially the Delta variants appeared as drivers of COVID-19 severity in Cameroon.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Sci Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Camarões

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Sci Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Camarões